Clinical Trial Update: Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation [Phase 2]

View source ↗

Summary

Phase 2 trial of oral LGD-4665 vs placebo in adults with immune thrombocytopenic purpura has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenic Purpura

Drugs mentioned

• LGD-4665

Snippet

Sponsor: GlaxoSmithKline | Conditions: Immune Thrombocytopenic Purpura | Phase 2 | Status: COMPLETED